** Shares of cancer drug developer CG Oncology CGON.O fall 0.5% to $28.72
** CGON late Thursday priced its stock offering of 8 mln shares at $28/shr
** Offering priced at a 3% discount to stock's last close
** Investment firm ORI Capital parted ways with 700,000 shares while CGON sold 7.3 mln shares in the stock offering
** Gross proceeds of roughly $204.4 mln from the offering for CGON, which will use it to fund the development of its experimental immunotherapy
** Morgan Stanley, Goldman Sachs, TD Cowen and Stifel were the joint book-running managers for the offering
** CGON went public in New York in January after raising $380 mln in its IPO at $19 offer price
** As of last close, CGON shares up 52% since debut on Jan. 25
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.